{
    "root": "f2da9a9d-f2dd-474e-a81e-dfbecd4d78b9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline",
    "value": "20250106",
    "ingredients": [
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9124"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        }
    ],
    "indications": {
        "text": "sertraline hydrochloride tablets indicated treatment following [ ( 14 ) ] : \u2022 major depressive disorder ( mdd ) \u2022 obsessive-compulsive disorder ( ocd ) \u2022 panic disorder ( pd ) \u2022 posttraumatic stress disorder ( ptsd ) \u2022 social anxiety disorder ( sad ) \u2022 premenstrual dysphoric disorder ( pmdd )",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "obsessive-compulsive disorder (DOID:10933)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10933"
            },
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "obsessive-compulsive disorder",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_C052"
            }
        ]
    },
    "contraindications": {
        "text": "indication starting maximum mdd ( 2.1 ) 50 mg per day 200 mg per day ocd ( 2.1 ) 25 mg per day ( ages 6 12 ) 200 mg per day 50 mg per day ( ages \u2265 13 ) pd , ptsd , sad ( 2.1 ) 25 mg per day 200 mg per day pmdd ( 2.2 ) continuous dosing 50 mg per day 150 mg per day pmdd ( 2.2 ) intermittent dosing 50 mg per day luteal phase 100 mg per day luteal phase \u2022 inadequate response starting , titrate 25 50 mg per day increments weekly mdd , ocd , pd , ptsd , sad ( 2.1 ) \u2022 full prescribing information titration pmdd ( 2.2 ) \u2022 hepatic impairment : mild : recommended starting maximum half recommended ( 2.4 ) moderate severe : recommended ( 2.4 ) \u2022 discontinuing sertraline hydrochloride , reduce dose gradually ( 2.6 , 5.4 )",
        "doid_entities": [
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sertraline hydrochloride tablets usp , 100 mg available light yellow , film coated , elliptical shaped tablets , scored one side tablet debossed `` 759 `` side . ndc : 72162-2411-0 : 1000 tablets bottle ndc : 72162-2411-1 : 100 tablets bottle ndc : 72162-2411-5 : 500 tablets bottle store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp . keep medications reach children . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "sertraline hydrochloride tablets contraindicated patients : taking , within 14 days stopping , maois , ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7.1 ) ] . taking pimozide [ ( 7.1 ) ] . known hypersensitivity sertraline ( e.g . , anaphylaxis , angioedema ) [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "Sertraline hydrochloride tablets are indicated for the treatment of the following [See Clinical Studies (14)]:\u2022 Major depressive disorder (MDD)\u2022 Obsessive-compulsive disorder (OCD)\u2022 Panic disorder (PD)\u2022 Posttraumatic stress disorder (PTSD)\u2022 Social anxiety disorder (SAD)\u2022 Premenstrual dysphoric disorder (PMDD)",
    "contraindications_original": "Indication Starting Dosage Maximum Dosage MDD\u00a0( 2.1 ) 50\u00a0mg\u00a0per\u00a0day 200\u00a0mg\u00a0per\u00a0day OCD\u00a0( 2.1 ) 25\u00a0mg\u00a0per\u00a0day\u00a0(ages\u00a06\u00a0to\u00a012) 200\u00a0mg\u00a0per\u00a0day 50\u00a0mg\u00a0per\u00a0day\u00a0(ages\u00a0\u2265\u00a013) PD,\u00a0PTSD,\u00a0SAD\u00a0( 2.1 ) 25\u00a0mg\u00a0per\u00a0day 200\u00a0mg\u00a0per\u00a0day PMDD\u00a0( 2.2 )\u00a0continuous\u00a0dosing 50\u00a0mg\u00a0per\u00a0day 150\u00a0mg\u00a0per\u00a0day PMDD\u00a0( 2.2 )\u00a0intermittent\u00a0dosing 50\u00a0mg\u00a0per\u00a0day\u00a0during\u00a0luteal\u00a0phase\u00a0only 100\u00a0mg\u00a0per\u00a0day\u00a0during\u00a0luteal\u00a0phase\u00a0only \u2022 If inadequate response to starting dosage, titrate in 25 to 50 mg per day increments once weekly in MDD,OCD, PD,PTSD,and SAD ( 2.1 ) \u2022 See Full Prescribing Information for titration in PMDD ( 2.2 ) \u2022 Hepatic impairment: Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) Moderate or severe: Not recommended ( 2.4 ) \u2022 When discontinuing sertraline hydrochloride, reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions_original": "Sertraline Hydrochloride Tablets USP, 100 mg are available as light yellow, film coated, elliptical shaped tablets, scored on one side of tablet and debossed with \"759\" on the other side.\n                  NDC: 72162-2411-0: 1000 Tablets in a BOTTLE\n                  NDC: 72162-2411-1: 100 Tablets in a BOTTLE\n                  NDC: 72162-2411-5: 500 Tablets in a BOTTLE\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP.\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Sertraline hydrochloride tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [See Warnings and Precautions (5.2), Drug Interactions (7.1)].\n                     Taking pimozide [See Drug Interactions (7.1)].\n                     With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [See Adverse Reactions (6.1, 6.2)].",
    "drug": [
        {
            "name": "Sertraline",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9123"
        }
    ]
}